The Company has four product candidates in development that address viral infections that have limited therapeutic options.

We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 & 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial.

In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.

Biota Pharmaceuticals was founded in 1984 and is headquartered in Alpharetta, US

Biota Pharmaceuticals has an office in Alpharetta

Alpharetta, US (HQ)

100 2500 Northwinds Pkwy

Biota Pharmaceuticals's revenue was reported to be $4.9 m in Q3, 2017

USD

## Revenue (Q3, 2017) | 4.9 m |

## Net income (Q3, 2017) | (4.4 m) |

## EBIT (Q3, 2017) | (3.8 m) |

## Cash (31-Mar-2017) | 11.8 m |

- Source: SEC Filings

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 68.7 m | 24.6 m | 9.3 m |

## Revenue growth, % | (64%) | (62%) | |

## Cost of goods sold | 51.1 m | 3.6 m | |

## Gross profit | 17.6 m | 21 m | |

## Gross profit Margin, % | 26% | 85% | |

## R&D expense | 26.3 m | ||

## General and administrative expense | 8 m | ||

## Operating expense total | 80.2 m | 44.1 m | 34.5 m |

## EBIT | (11.5 m) | (19.5 m) | (25.2 m) |

## EBIT margin, % | (17%) | (79%) | (271%) |

## Net Income | (11 m) | (19.1 m) | (25.4 m) |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 700 k | 13.9 m | 5.9 m | 1.7 m | 1.7 m | 5.3 m | 100 k | 3.8 m | 4.9 m |

## Cost of goods sold | 1.7 m | 1.6 m | 300 k | ||||||

## Gross profit | (1 m) | 12.3 m | 5.6 m | ||||||

## Gross profit Margin, % | (143%) | 88% | 95% | ||||||

## R&D expense | 4.9 m | 4.8 m | 4.8 m | 5.5 m | 6.3 m | 8.5 m | 7.6 m | 10.2 m | 6.8 m |

## General and administrative expense | 2.4 m | 2.6 m | 3.2 m | 2.2 m | 2.1 m | 2.3 m | 2.2 m | 2.1 m | 1.8 m |

## Operating expense total | 7.3 m | 7.4 m | 8 m | 7.7 m | 8.4 m | 10.8 m | 9.8 m | 12.3 m | 8.6 m |

## EBIT | (7 m) | 6.4 m | 1.1 m | (6.7 m) | (6.5 m) | (5.2 m) | (9.6 m) | (8.6 m) | (3.8 m) |

## EBIT margin, % | (1000%) | 46% | 19% | (394%) | (382%) | (98%) | (9600%) | (226%) | (78%) |

## Interest income | 100 k | 100 k | 100 k | 100 k | 100 k | 100 k | |||

## Pre tax profit | (6.6 m) | ||||||||

## Income tax expense | 100 k | 200 k | |||||||

## Net Income | (6.9 m) | 6.5 m | 1.2 m | (6.6 m) | (6.5 m) | (5.2 m) | (10 m) | (9.1 m) | (4.4 m) |

- Source: SEC Filings

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 81.7 m | 44.7 m | 49.7 m |

## Current Assets | 101.1 m | 70.8 m | 72.4 m |

## PP&E | 2 m | 200 k | 300 k |

## Total Assets | 114 m | 79.4 m | 72.7 m |

## Accounts Payable | 2.8 m | 1.9 m | 3.9 m |

## Current Liabilities | 26.9 m | 9 m | 9.2 m |

## Total Liabilities | 26.5 m | ||

## Additional Paid-in Capital | 146.4 m | 155.6 m | 157.6 m |

## Retained Earnings | (89.8 m) | (108.9 m) | (134.3 m) |

## Total Equity | 86.9 m | 69.5 m | 46.2 m |

## Financial Leverage | 1.3 x | 1.1 x | 1.6 x |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 57.7 m | 63.7 m | 61.5 m | 45.3 m | 39 m | 30.6 m | 45.9 m | 38.1 m | 11.8 m |

## Accounts Receivable | 10.1 m | 3.2 m | |||||||

## Current Assets | 76.1 m | 86.2 m | 87.4 m | 61.2 m | 58.6 m | 60.5 m | 62.8 m | 56.2 m | 46.4 m |

## PP&E | 1.6 m | 1.1 m | 300 k | 200 k | 400 k | 400 k | 300 k | 300 k | 300 k |

## Total Assets | 97.3 m | 93.4 m | 88.8 m | 71 m | 64.2 m | 61.9 m | 63.1 m | 56.5 m | 46.7 m |

## Accounts Payable | 1.4 m | 1.7 m | 1 m | 2.9 m | 1.3 m | 3.7 m | 1.6 m | 3.4 m | 1.8 m |

## Current Liabilities | 19.3 m | 10.9 m | 7.2 m | 6.7 m | 6 m | 8.7 m | 8.8 m | 10.5 m | 5.5 m |

## Additional Paid-in Capital | 146.8 m | 147.4 m | 148 m | 156.2 m | 156.8 m | 157.2 m | 158 m | 158.5 m | 159.1 m |

## Retained Earnings | (96.7 m) | (90.2 m) | (89 m) | (115.5 m) | (122.1 m) | (127.3 m) | (144.3 m) | (153.4 m) | (157.8 m) |

## Total Equity | 63.5 m | 57.5 m | 52.7 m | 36.6 m | 28 m | 24.2 m | |||

## Financial Leverage | 1.1 x | 1.1 x | 1.2 x | 1.7 x | 2 x | 1.9 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (11 m) | (19.1 m) | (25.4 m) |

## Depreciation and Amortization | 2.4 m | 1.1 m | 100 k |

## Accounts Receivable | (7.1 m) | 6.2 m | 11.9 m |

## Cash From Operating Activities | (3.3 m) | (9.6 m) | (14.1 m) |

## Purchases of PP&E | (100 k) | (100 k) | (200 k) |

## Cash From Investing Activities | (10.1 m) | (19.4 m) | 1.3 m |

## Cash From Financing Activities | 26.8 m | (100 k) | 17.8 m |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (6.9 m) | 6.5 m | 1.2 m | (6.6 m) | (6.5 m) | (5.2 m) | (10 m) | (9.1 m) | (4.4 m) |

## Accounts Receivable | 10.1 m | 3.2 m | |||||||

## Accounts Payable | 1.4 m | 1.7 m | 1 m | 2.9 m | 1.3 m | 3.7 m | 1.6 m | 3.4 m | 1.8 m |

Y, 2017 | |
---|---|

## Financial Leverage | 1.9 x |